ixekizumab
eli lilly
[' psa', 'ixekizumab', ' ixe ']
il-17i ixekizumab (ixe) continuation superior to withdrawal in preventing relapse in psa withdrawal resulted in relapse at median 22 wk continuation vs withdrawal 38% vs 85% relapse 96% regained control after reinstating ixe jose scher #reviewcourse #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach